Ever Supreme Bio Technology Co., Ltd
Research Ever Supreme Bio Technology Co., Ltd (6712.TWO) on Bullrun: market cap TWD 15.78B, P/E 31.9, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6712.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 15.78B
- P/E31.9
- Dividend yield2.3%
- Financial periodQ2 2026
- RevenueTWD 272.06M
- Net incomeTWD 90.05M
- Free cash flowTWD 140.72M
- Gross margin76.9%
Valuation Snapshot
latest market cap is TWD 15.78B; P/E is 31.9; dividend yield is 2.3%.
Peer valuation comparison
Latest P/E is 31.91x versus a Healthcare sector median of 21.8x (46.4% above).
Latest dividend yield is 2.25% versus a Healthcare sector median of 2.4% (6.2% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 15.78B | 31.9 | 2.1% | 3.33 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.33 TWD, yield 2.3%.
About Ever Supreme Bio Technology Co., Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke.
ETFs that hold Ever Supreme Bio Technology Co., Ltd
US-listed ETFs
Ever Supreme Bio Technology Co., Ltd is held by 9 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| Dimensional Emerging Markets Value ETF (DFEV) | 0.01% | 0.43% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.04% | 0.65% |
| Dimensional Emerging Markets ex China Core Equity ETF (DEXC) | 0.01% | 0.43% |
| Dimensional Emerging Markets Sustainability Core 1 ETF (DFSE) | <0.01% | 0.41% |
Portfolios as filed with the SEC on Form N-PORT, dated June to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ever Supreme Bio Technology Co., Ltd's market cap?
Ever Supreme Bio Technology Co., Ltd's market capitalization is TWD 15.78B.
What is Ever Supreme Bio Technology Co., Ltd's P/E ratio?
Ever Supreme Bio Technology Co., Ltd's price-to-earnings (P/E) ratio is 31.9.
Does Ever Supreme Bio Technology Co., Ltd pay a dividend?
Ever Supreme Bio Technology Co., Ltd has a dividend yield of 2.3%.
What does Ever Supreme Bio Technology Co., Ltd do?
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke.